This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / Myriad Genetics launches Prolaris + AI Test
Tech product launch

Myriad Genetics launches Prolaris + AI Test

Analysis based on 6 articles · First reported May 26, 2026 · Last updated May 26, 2026

Sentiment
70
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The launch of the Prolaris + AI Test by Myriad Genetics is expected to positively impact its stock price due to an expanded product portfolio and enhanced diagnostic capabilities in prostate cancer. This innovation could also drive increased adoption of advanced diagnostic tools in the healthcare sector, benefiting companies involved in precision medicine and AI-powered diagnostics.

Biotechnology Healthcare Artificial intelligence
Event Summary

Myriad Genetics, a leader in molecular diagnostic testing, announced the launch of its Prolaris + AI Test at the end of May 2026. This new test is the first and only prostate cancer biomarker test to integrate clinical-pathological features, a molecular score, and AI-powered digital pathology technology from Pathomiq. The Prolaris + AI Test aims to help clinicians more confidently identify patients suitable for active surveillance and personalize surveillance intensity, addressing a critical gap in prostate cancer management. The AI metric will be available for all Prolaris Biopsy Tests in the United States, excluding New York State initially, with approval for New York State expected soon. Ann Donnelly, Chief Commercial Officer of Myriad Genetics, highlighted the significant progress this test represents for prostate cancer patients and providers.

Entities Involved
stock
Myriad Genetics
Myriad Genetics launched the Prolaris + AI Test, a new prostate cancer biomarker test, which is expected to enhance its product offerings and market position in precision medicine.
Importance 100.0 Sentiment 75.0
priv
Pathomiq
Pathomiq's AI technology is integrated into the new Prolaris + AI Test, demonstrating the value of its digital pathology AI platform and potentially increasing its visibility and partnerships.
Importance 80.0 Sentiment 60.0
per
Ann Donnelly
Ann Donnelly, Chief Commercial Officer of Myriad Genetics, commented on the significance of the Prolaris + AI Test for prostate cancer management.
Importance 30.0 Sentiment 0.0
cnt
United States
The Prolaris + AI Test will be available in the United States, excluding New York State initially, addressing a significant healthcare need within the country.
Importance 20.0 Sentiment 0.0
loc
United States — New York (state)
Approval for the Prolaris + AI Test in New York State is pending, indicating a temporary delay in market access for this specific region.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.